Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Edward Morrow Atkinson III currently holds 18,432 shares of VERTEX PHARMACEUTICALS INC / MA (VRTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Edward Morrow Atkinson III has been a net seller of VRTX stock. They have purchased $0 and sold $6.7M worth of shares.
Edward Morrow Atkinson III's most recent insider trade was on Feb 25, 2026, when they sold 668 shares at $486.35 per share.
Edward Morrow Atkinson III serves as Executive at VERTEX PHARMACEUTICALS INC / MA (VRTX). They have executed 22 insider transactions totaling $6.7M over their tenure at the company.
Edward Morrow Atkinson III holds the position of Executive at VERTEX PHARMACEUTICALS INC / MA, where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 3 years and currently hold a stake valued at $0.
Edward Morrow Atkinson III has shown a selling trading pattern, with $0 in total purchases and $6.7M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Edward Morrow Atkinson III was on Jun 12, 2024, when they sold $3.5M worth of VRTX shares. This transaction involved 7,288 shares at $478.00 per share.
Edward Morrow Atkinson III currently owns 18,432 shares of VERTEX PHARMACEUTICALS INC / MA (VRTX), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Edward Morrow Atkinson III's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Edward Morrow Atkinson III has 22 Form 4 filings on record as an insider at VERTEX PHARMACEUTICALS INC / MA.
Set alerts for Edward Morrow Atkinson III and 40,000+ other insiders.